# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

> **NCT03547167** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1515 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** PNEUMOVAX™23

## Key facts

- **NCT ID:** NCT03547167
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-01-20
- **Target enrollment:** 1515 (ACTUAL)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547167, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03547167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*